ALX Oncology
ALXO
114 hedge funds and large institutions have $2.55B invested in ALX Oncology in 2021 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 34 increasing their positions, 34 reducing their positions, and 15 closing their positions.
214% more call options, than puts
Call options by funds: $5.77M | Put options by funds: $1.84M
67% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 15
40% more capital invested
Capital invested by funds: $1.82B → $2.55B (+$727M)
9% more funds holding
Funds holding: 105 → 114 (+9)
2.72% more ownership
Funds ownership: 82.82% → 85.54% (+2.7%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
0% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 34
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$64.7M |
| 2 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$37.1M |
| 3 |
Invesco
Atlanta,
Georgia
|
+$33.8M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$8.65M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$8.17M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$24.1M |
| 2 |
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University
Redwood City,
California
|
-$14.2M |
| 3 |
Janus Henderson Group
London,
|
-$13.2M |
| 4 |
State Street
Boston,
Massachusetts
|
-$12.9M |
| 5 |
FCMV
Foresite Capital Management V
Larkspur,
California
|
-$12.6M |
ALXO Hedge Fund Activity: Q3 2021 in Review
114 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in ALX Oncology (ALXO) for Q3 2021, worth a combined $2.55B — up 40% from $1.82B a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new ALXO positions and 15 closed out — a net gain of 10 holders — while 34 added to existing stakes and 34 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $64.7M. The largest seller was Eventide Asset Management, exiting entirely with an estimated $24.1M sold.
- 114 institutional investors held ALX Oncology (ALXO) as of Q3 2021, up from 105 in Q2 2021.
- Funds reported $2.55B of ALX Oncology stock for Q3 2021, up 40% quarter-over-quarter.
- 25 funds opened new ALX Oncology positions in Q3 2021 and 15 closed out, a net change of +10 holders.
- The largest ALX Oncology buyer in Q3 2021 was Wellington Management Group, an estimated $64.7M added.
- The largest ALX Oncology seller in Q3 2021 was Eventide Asset Management, an estimated $24.1M sold.
Based on aggregated 13F filings for Q3 2021.